Moderna posts Q1 2024 revenues at US$167 million

GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)

Merck announces positive data for investigational, 21-Valent pneumococcal conjugate vaccine

Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infectious Diseases

AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024

New data for Tezspire and Breztri demonstrate AstraZeneca’s innovation and commitment to transform care in COPD

Pfizer expects full-year 2024 revenues between US$ 58.5 to US$ 61.5 billion

First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter

Lilly posts Q1 2024 revenue up 26% at US$ 8.77 billion

2024 full-year revenue guidance raised by US$ 2 billion

Gland Pharma receives approval for cetrorelix acetate for injection

AstraZeneca’s Truqap plus Faslodex recommended for approval in the EU by CHMP for cancer treatment

Recommendation based on CAPItello-291 results which showed the Truqap combination reduced the risk of disease progression or death by 50%

Parexel and Palantir to accelerate clinical data delivery and power clinical outcomes for patients

Parexel will leverage Palantir’s Foundry and Artificial Intelligence Platform to further power its clinical data platform

Apollo HealthCo to raise Rs. 2,475 crore from Advent International

Keimed is a leading wholesale pharma distribution with industry leading operating metrics

CHMP adopts positive opinion recommending approval of Bristol Myers Squibb’s Opdivo in combination with Cisplatin and Gemcitabine

If approved, the Opdivo-based regimen would be the first immunotherapy-chemotherapy combination approved for this patient population in the EU